The estimated Net Worth of Joan Stafslien is at least 2.6 千$ dollars as of 19 November 2020. Joan Stafslien owns over 4,410 units of Catheter Precision stock worth over 2,602$ and over the last 8 years Joan sold RMED stock worth over 0$.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Joan Stafslien RMED stock SEC Form 4 insiders trading
Joan has made over 2 trades of the Catheter Precision stock since 2016, according to the Form 4 filled with the SEC. Most recently Joan bought 4,410 units of RMED stock worth 25,005$ on 19 November 2020.
The largest trade Joan's ever made was buying 5,000 units of Catheter Precision stock on 31 October 2016 worth over 298,400$. On average, Joan trades about 1,568 units every 247 days since 2016. As of 19 November 2020 Joan still owns at least 4,410 units of Catheter Precision stock.
You can see the complete history of Joan Stafslien stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Joan Stafslien's mailing address?
Joan's mailing address filed with the SEC is C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD, CA, 92011.
Insiders trading at Catheter Precision
Over the last 6 years, insiders at Catheter Precision have traded over 709,539$ worth of Catheter Precision stock and bought 199,373 units worth 197,741$ . The most active insiders traders include Jeffrey J Kraws、Jonathan Will Mc Guire、Dean Burstein Melissa Dean .... On average, Catheter Precision executives and independent directors trade stock every 34 days with the average trade being worth of 12,983$. The most recent stock trade was executed by Andrew C. Jackson on 20 November 2021, trading 2,684 units of RMED stock currently worth 7,032$.
What does Catheter Precision do?
advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of
What does Catheter Precision's logo look like?
Complete history of Joan Stafslien stock trades at Nuvasive Inc、Catheter Precision
Catheter Precision executives and stock owners
Catheter Precision executives and other stock owners filed with the SEC include:
-
Jonathan Will McGuire,
CEO & Director -
Andrew C. Jackson,
Chief Financial Officer -
Brian D. Conn,
Interim CFO, Principal Financial Officer & Principal Accounting Officer -
Al Memmolo B.S. MBA,
Sr. VP of Clinical, Quality & Regulatory Affairs -
Maria Villanueva,
VP & Compliance Officer -
Tiah Reppas,
VP, Chief Accounting Officer & Corp. Controller -
James Joseph Caruso,
-
Dean Dean Irwin & Melissa B...,
See Remarks -
Joan Stafslien,
Director -
Martin Martin Burstein Livi...,
-
William R Enquist,
Director -
Maurice Buchbinder,
Director -
Daniel Horwood,
General Counsel -
Richard Jr Mejia,
Director -
Martin J Colombatto,
Director -
Mark E Saad,
Director -
Dean Burstein Melissa Dean ...,
-
Thomas G Fogarty,
See Remarks -
Jeffrey J Kraws,
Co-President -
David A Jenkins,
Ex. Chairman of the Board -
Andrew C. Jackson,
CFO -
Dean Irwin,
10% owner -
Susanne Meline,
-
Jonathan Will Mc Guire,
CEO & Secretary